Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

Rhea-AI Summary

Amneal (Nasdaq: AMRX) reported Q4 2025 net revenue of $814 million and GAAP net income of $35 million (diluted EPS $0.11). Full‑year 2025 net revenue was $3.02 billion with GAAP net income of $72 million and adjusted diluted EPS of $0.83. The company provided 2026 guidance of $3.05–3.15 billion revenue, $720–760 million adjusted EBITDA and $0.93–1.03 adjusted diluted EPS.

The release highlights Specialty growth (CREXONT, UNITHROID), new branded launches, and AvKARE strength, while management reiterated assumptions behind non‑GAAP reconciliations and provided a Feb. 27, 2026 webcast for investors.

Positive

• Full‑year revenue +8% to $3.02 billion
• Specialty revenue +19% year‑over‑year
• Adjusted EBITDA +10% to $688 million
• Q4 revenue +11% to $814 million
• 2026 guidance: Adjusted EBITDA $720–760M and revenue $3.05–3.15B

Negative

• GAAP net income of $72M vs adjusted net income of $269M
• Specialty guidance expected to be flat year‑over‑year in 2026
• Company cannot reconcile non‑GAAP projections to GAAP without unreasonable efforts

News Market Reaction – AMRX

-4.69%

1 alert

-4.69% News Effect

On the day this news was published, AMRX declined 4.69%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q4 2025 net revenue: $814 million Q4 2025 GAAP net income: $35 million Q4 2025 Adjusted EBITDA: $175 million +5 more

8 metrics

Q4 2025 net revenue $814 million Fourth quarter 2025

Q4 2025 GAAP net income $35 million Fourth quarter 2025

Q4 2025 Adjusted EBITDA $175 million Fourth quarter 2025

FY 2025 net revenue $3.02 billion Full year 2025

FY 2025 GAAP net income $72 million Full year 2025

FY 2025 Adjusted EBITDA $688 million Full year 2025

2026 revenue guidance $3.05–$3.15 billion Full year 2026 guidance

2026 Adjusted EBITDA guidance $720–$760 million Full year 2026 guidance

Market Reality Check

Price: $13.81 Vol: Volume 1,986,118 is below...

low vol

$13.81 Last Close

Volume Volume 1,986,118 is below its 20-day average of 3,605,695 (relative volume 0.55x). low

Technical Price $14.49 is trading above the 200-day MA $10.48 and sits 6.03% below the 52-week high.

Peers on Argus

Pre-news, peers showed mixed moves: PRGO up 6.69%, while INDV, BHC, and HCM were...

1 Up 1 Down

Pre-news, peers showed mixed moves: PRGO up 6.69%, while INDV, BHC, and HCM were down modestly. Momentum scanner flagged one peer up (ANIP +2.28%) and one down (LNTH −2.82%), suggesting stock-specific drivers rather than a broad sector rotation.

Previous Earnings Reports

5 past events · Latest: Oct 30 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 30	Q3 2025 earnings	Positive	-4.1%	Reported Q3 growth and raised 2025 guidance for revenue and EBITDA.
Aug 05	Q2 2025 earnings	Positive	+2.1%	Strong Q2 growth, higher adjusted EBITDA and EPS, plus $2.7B refinancing.
Jul 21	Prelim Q2 2025	Positive	-0.8%	Preliminary Q2 beat indications with leverage improvement and product wins.
May 02	Q1 2025 earnings	Positive	+3.0%	Q1 growth across segments with higher adjusted EBITDA and EPS.
Feb 28	FY 2024 earnings	Positive	+3.5%	Strong 2024 growth and initial 2025 guidance for revenue and EBITDA.

Pattern Detected

Earnings releases have generally been received positively, but two of the last five showed short-term share price declines despite fundamentally strong results and guidance updates.

Recent Company History

Across the past year, Amneal’s earnings releases highlighted steady growth and improving profitability. Q1–Q3 2025 results showed rising net revenue, GAAP profitability, and increasing adjusted EBITDA, with multiple guidance raises and a major $2.7 billion debt refinancing. The 2024 year-end report set an initial $3.0–$3.1 billion 2025 revenue target and higher EBITDA goals. Today’s Q4 and full-year 2025 results confirm net revenue of $3.02 billion and adjusted EBITDA of $688 million, meeting or exceeding these prior objectives.

Historical Comparison

+0.7% avg move · Over the last five earnings-related releases, AMRX moved an average of 0.74% in the following sessio...

earnings

+0.7%

Average Historical Move earnings

Over the last five earnings-related releases, AMRX moved an average of 0.74% in the following session, with mostly favorable reactions but some sell-the-news episodes after strong reports.

Earnings updates over 2024–2025 showed a progression from strong 2024 growth to steadily improving 2025 quarters, with repeated guidance raises. Today’s Q4 and full-year 2025 report confirms delivery at the upper end of earlier revenue and EBITDA ranges and extends that trajectory via 2026 guidance for further growth.

Market Pulse Summary

This announcement details Q4 and full-year 2025 results that met or exceeded prior guidance and sets...

Analysis

This announcement details Q4 and full-year 2025 results that met or exceeded prior guidance and sets 2026 targets for further growth in net revenue, adjusted EBITDA, and adjusted EPS. Historical earnings releases show consistent expansion across segments and improving profitability. Investors may focus on execution versus the new 2026 ranges, the mix between GAAP and non-GAAP performance, and how product launches and segment trends support sustained cash generation and balance-sheet strength.

Key Terms

adjusted net income, adjusted ebitda, adjusted diluted eps, non-gaap, +2 more

6 terms

adjusted net income financial

"Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million"

Adjusted net income is a company's reported profit after removing unusual, one-time, or non-operational items so the number reflects the business’s regular earning power. Investors use it like a cleaned-up scorecard — similar to judging a player’s season performance without a few fluke games — to compare companies or assess trends without being misled by rare gains or losses that won’t affect future cash flow.

adjusted ebitda financial

"Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

adjusted diluted eps financial

"Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Adjusted Net Income"

Adjusted diluted EPS is a company’s profit per share after adding back or removing one-time items (like restructuring costs or gains) and dividing by the number of shares including potential shares from options and convertible securities. Investors use it as a cleaner view of ongoing earnings—like looking at a car’s regular fuel efficiency rather than a trip boosted by downhill coasting—to judge underlying performance and compare companies without temporary distortions.

non-gaap financial

"The Company presents GAAP and adjusted (non-GAAP) quarterly and full-year results."

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

gaap financial

"The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)."

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

weighted-average diluted shares outstanding financial

"Assumes weighted-average diluted shares outstanding of ~330 million for the year ending December 31, 2026"

Weighted-average diluted shares outstanding is the average number of company shares that existed during a reporting period after adding any shares that could be created from options, warrants or convertible securities, with each potential share counted only for the portion of the period it could have existed. Investors use this figure to calculate diluted earnings per share and other per-share metrics; it’s like averaging the number of seats at a table when some guests might arrive or leave, so earnings are fairly spread over all possible shares.

AI-generated analysis. Not financial advice.

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth –

‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒
‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒

‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒
‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒

‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS –

BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2025.

“We are extremely pleased with Amneal’s sixth consecutive year of consistent execution and strong growth. Our full year 2025 performance highlights the durability of our diversified portfolio and the successful execution of our strategy. In Specialty, CREXONT® continues to see strong uptake, and we successfully launched our newest branded product, the BREKIYA® autoinjector. In Affordable Medicines, we delivered a robust cadence of new product approvals, including our first two inhalation products and our fourth and fifth biosimilars. Looking ahead, we believe Amneal is very well positioned to deliver substantial growth and create long-term value for years to come,” said Chirag and Chintu Patel, Co-Chief Executive Officers.

Net revenue in the fourth quarter of 2025 was $814 million, an increase of 11% compared to $731 million in the fourth quarter of 2024. Specialty net revenue increased 38% driven by CREXONT® and UNITHROID®. Affordable Medicines net revenue decreased 1% due to the timing of revenue for key products and new launches. AvKARE net revenue increased 24% driven by growth in the government label sales channel. Net income attributable to Amneal Pharmaceuticals, Inc. was $35 million in the fourth quarter of 2025 compared to a net loss of $31 million in the fourth quarter of 2024, reflecting higher revenue and gross profit and lower operating expense. Adjusted EBITDA in the fourth quarter of 2025 was $175 million, an increase of 13% compared to the fourth quarter of 2024, reflective of higher revenue and gross profit, partially offset by commercial investments. Diluted income per share in the fourth quarter of 2025 was $0.11 compared to a loss of $0.10 for the fourth quarter of 2024 due to the aforementioned factors as well as lower interest expense. Adjusted diluted EPS in the fourth quarter of 2025 was $0.21 compared to $0.12 in the fourth quarter of 2024.

Net revenue for the year ended December 31, 2025 was $3.02 billion, an increase of 8%, compared to $2.79 billion for the year ended December 31, 2024. Revenues for each of the business segments increased in 2025 with Specialty growing 19%, Affordable Medicines growing 4%, and AvKARE growing 12%. Net income attributable to Amneal Pharmaceuticals, Inc. was $72 million for the year ended December 31, 2025 compared to a net loss of $117 million for the year ended December 31, 2024, due to higher revenue and gross profit, and lower expenses. Adjusted EBITDA for the year ended December 31, 2025 was $688 million, an increase of 10% compared to the prior year, reflective of higher revenue and gross profit and operating leverage in selling, general and administrative expenses and research and development expenses, partially offset by increased commercial investments. Diluted income per share for the year ended December 31, 2025 was $0.22 compared to diluted loss per share of $0.38 for the year ended December 31, 2024 due to the aforementioned factors as well as lower interest expense. Adjusted diluted EPS in the year ended December 31, 2025 was $0.83 compared to $0.58 for the year ended December 31, 2024.

The Company presents GAAP and adjusted (non-GAAP) quarterly and full-year results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.

2026 Full Year Financial Guidance

	2026 Guidance	2025 Actuals
Net revenue (1)	$3.05 billion - $3.15 billion	$3.02 billion
Adjusted EBITDA (2)	$720 million - $760 million	$688 million
Adjusted diluted EPS (3)	$0.93 - $1.03	$0.83
Operating cash flow	$325 million - $375 million	$340 million
Operating cash flow, excluding discrete items (4)	$350 million - $400 million	$340 million
Capital expenditures (5)	~$110 million	$89 million

(1)	The Company expects Affordable Medicines net revenue to grow 7% to 8%, Specialty net revenue to be flat year-over-year, and AvKARE to generate $625 million to $700 million net revenue.
(2)	Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.
(3)	Accounts for 35% non-controlling interest in AvKARE. Assumes weighted-average diluted shares outstanding of ~330 million for the year ending December 31, 2026, compared to weighted-average diluted shares outstanding of 325 million for the year ended December 31, 2025. See also “Non-GAAP Financial Measures” below for assumptions used in the calculation of weighted-average diluted shares.
(4)	Excludes discrete items such as legal settlement payments.
(5)	Reflects actual purchases and deposits for future acquisition of property, plant, and equipment, net of contributions from an alliance party.

Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Conference Call Information

Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, February 27, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 937407. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=94630.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit www.amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our positioning and potential growth, statements regarding our ability to create long-term value, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted operating cash flow and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income (loss), which is net income (loss) adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for income taxes, (iii) amortization, (iv) stock-based compensation expense, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing, (viii) charges (credit) related to certain legal matters, including interest, net, (ix) asset impairment charges, (x) increase in tax receivable agreement liability, (xi) other and (xii) net income attributable to non-controlling interests, and (B) include non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three months and year ended December 31, 2025 and 2024 was calculated using the weighted average fully diluted shares outstanding of Class A common stock (inclusive of the effect of dilutive securities).

EBITDA reflects net income (loss) adjusted to exclude interest expense, net, provision for income taxes and depreciation and amortization. Adjusted EBITDA reflects net income (loss) adjusted to exclude (i) interest expense, net, (ii) provision for income taxes, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) acquisition, site closure, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing, (viii) charges (credit) related to legal matters, net, (ix) asset impairment charges, (x) foreign exchange loss (gain), (xi) increase in tax receivable agreement liability, and (xii) other.

Adjusted operating cash flow reflects cash flow from operations excluding discrete items such as legal settlement payments.

Net leverage is calculated as net debt (total outstanding principal on the Company’s debt, less cash and cash equivalents) divided by adjusted EBITDA for the year or the trailing twelve-month period then ended.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Amneal Pharmaceuticals, Inc. Consolidated Statements of Operations (unaudited; $ in thousands, except per share amounts)
	Three Months Ended December 31,								Year Ended December 31,
	2025				2024				2025				2024
Net revenue	$	814,319			$	730,518			$	3,018,760			$	2,793,957
Cost of goods sold		517,129				467,645				1,905,452				1,773,519
Gross profit		297,190				262,873				1,113,308				1,020,438
Selling, general and administrative		146,458				128,687				526,827				476,436
Research and development		34,819				54,265				186,175				190,714
Intellectual property legal development expenses		1,411				1,852				7,632				5,845
Restructuring and other charges		2,470				493				4,208				2,355
Charges (credit) related to legal matters, net		—				1,783				(390	)			96,692
Other operating income		(1	)			—				(5,240	)			(930	)
Operating income		112,033				75,793				394,096				249,326
Other (expense) income:
Interest expense, net		(56,237	)			(61,662	)			(241,091	)			(258,595	)
Foreign exchange (loss) gain, net		(1,437	)			(7,661	)			7,635				(6,846	)
Loss on refinancing		—				—				(31,365	)			—
Increase in tax receivable agreement liability		(12,289	)			(23,961	)			(6,588	)			(50,680	)
Other income, net		13,165				2,172				16,522				11,782
Total other expense, net		(56,798	)			(91,112	)			(254,887	)			(304,339	)
Income (loss) before income taxes		55,235				(15,319	)			139,209				(55,013	)
Provision for income taxes		5,662				5,423				11,276				18,863
Net income (loss)		49,573				(20,742	)			127,933				(73,876	)
Less: Net income attributable to non-controlling interests		(14,497	)			(10,339	)			(55,876	)			(43,010	)
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	$	35,076			$	(31,081	)		$	72,057			$	(116,886	)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic	$	0.11			$	(0.10	)		$	0.23			$	(0.38	)
Diluted	$	0.11			$	(0.10	)		$	0.22			$	(0.38	)
Weighted-average common shares outstanding:
Basic		314,462				309,850				313,367				308,978
Diluted		328,094				309,850				324,805				308,978

Amneal Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (unaudited; $ in thousands)
	December 31, 2025				December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	282,029			$	110,552
Restricted cash		28,842				7,868
Trade accounts receivable, net		895,143				775,731
Inventories		606,302				612,454
Prepaid expenses and other current assets		98,395				80,717
Related party receivables		470				484
Total current assets		1,911,181				1,587,806
Property, plant and equipment, net		442,950				424,908
Goodwill		595,470				597,436
Intangible assets, net		563,498				732,377
Operating lease right-of-use assets		38,832				31,388
Operating lease right-of-use assets - related party		15,216				10,964
Financing lease right-of-use assets		53,328				56,433
Other assets		57,805				60,133
Total assets	$	3,678,280			$	3,501,445
Liabilities and Stockholders’ Deficiency
Current liabilities:
Accounts payable and accrued expenses	$	761,316			$	735,450
Current portion of liabilities for legal matters		43,256				31,755
Revolving credit facility		—				100,000
Current portion of long-term debt, net		6,761				224,213
Current portion of operating lease liabilities		8,668				9,435
Current portion of operating lease liabilities - related party		2,705				3,396
Current portion of financing lease liabilities		3,442				3,211
Related party payables - short term		55,485				22,311
Total current liabilities		881,633				1,129,771
Long-term debt, net		2,565,115				2,161,790
Operating lease liabilities		33,233				24,814
Operating lease liabilities - related party		14,195				9,391
Financing lease liabilities		54,927				56,889
Related party payable - long term		19,132				50,900
Liabilities for legal matters - long term		71,819				85,479
Other long-term liabilities		32,263				26,949
Total long-term liabilities		2,790,684				2,416,212
Redeemable non-controlling interests		77,292				64,974
Total stockholders’ deficiency		(71,329	)			(109,512	)
Total liabilities and stockholders’ deficiency	$	3,678,280			$	3,501,445

Amneal Pharmaceuticals, Inc. Consolidated Statements of Cash Flows (unaudited; $ in thousands)
	Years Ended December 31,
	2025				2024
Cash flows from operating activities:
Net income (loss)	$	127,933			$	(73,876	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization		223,572				236,191
Unrealized foreign currency (gain) loss		(7,453	)			7,191
Amortization of debt issuance costs and discount		22,431				29,097
Reclassification of cash flow hedge		1,229				(26,205	)
Loss on refinancing		31,365				—
Intangible asset impairment charges		22,784				920
Stock-based compensation		31,953				27,768
Inventory provision		85,962				96,558
Other operating charges and credits, net		4,732				1,523
Changes in assets and liabilities:
Trade accounts receivable, net		(120,566	)			(162,637	)
Inventories		(87,026	)			(130,530	)
Prepaid expenses, other current assets and other assets		(19,163	)			(959	)
Related party receivables		(13	)			482
Accounts payable, accrued expenses and other liabilities		21,321				235,135
Related party payables		931				54,441
Net cash provided by operating activities		339,992				295,099
Cash flows from investing activities:
Purchases of property, plant and equipment		(70,063	)			(51,924	)
Acquisition of intangible assets		(15,514	)			(14,650	)
Deposits for future acquisition of property, plant, and equipment		(28,780	)			(8,416	)
Proceeds from sale of property, plant, equipment and other		2,094				—
Proceeds from sale of subsidiary		—				11,994
Net cash used in investing activities		(112,263	)			(62,996	)
Cash flows from financing activities:
Proceeds from issuance of debt		2,694,750				—
Payments of principal on debt, revolving credit facility, financing leases and other		(2,811,508	)			(188,918	)
Payments of deferred financing, refinancing costs and debt extinguishment costs		(74,973	)			(71	)
Borrowings on revolving credit facility		218,000				48,000
Proceeds from exercise of stock options		1,960				1,154
Employee payroll tax withholding on restricted stock unit and performance stock unit vesting		(22,278	)			(7,952	)
Tax and other distributions to non-controlling interests		(43,848	)			(19,804	)
Payment of principal on notes payable - related party		—				(44,200	)
Proceeds from alliance party		6,367				—
Net cash used in financing activities		(31,530	)			(211,791	)
Effect of foreign exchange rate on cash		(1,680	)			(999	)
Net increase in cash, cash equivalents, and restricted cash		194,519				19,313
Cash, cash equivalents, and restricted cash - beginning of period		118,420				99,107
Cash, cash equivalents, and restricted cash - end of period	$	312,939			$	118,420
Cash and cash equivalents - end of period	$	282,029			$	110,552
Restricted cash - end of period		28,842				7,868
Long-term restricted cash included in other assets - end of period		2,068				—
Cash, cash equivalents, and restricted cash - end of period	$	312,939			$	118,420

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands)
Reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA
	Three Months Ended December 31,								Year Ended December 31,
	2025				2024				2025				2024
Net income (loss)	$	49,573			$	(20,742	)		$	127,933			$	(73,876	)
Adjusted to add:
Interest expense, net		56,237				61,662				241,091				258,595
Provision for income taxes		5,662				5,423				11,276				18,863
Depreciation and amortization		49,227				66,130				223,572				236,191
EBITDA (Non-GAAP)	$	160,699			$	112,473			$	603,872			$	439,773
Adjusted to add (deduct):
Stock-based compensation expense		8,202				7,209				31,823				27,552
Acquisition, site closure, and idle facility expenses (1)		539				538				5,301				2,112
Restructuring and other charges		2,470				493				4,208				2,265
Loss on refinancing (2)		—				—				31,365				—
Charges (credit) related to legal matters, net (3)		—				1,783				(390	)			96,692
Asset impairment charges		134				176				23,022				1,372
Foreign exchange loss (gain)		1,437				7,661				(7,635	)			6,846
Increase in tax receivable agreement liability		12,289				23,961				6,588				50,680
Other (4)		(10,568	)			963				(9,739	)			150
Adjusted EBITDA (Non-GAAP)	$	175,202			$	155,257			$	688,415			$	627,442

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands)
Calculation of Net Debt and Net Leverage
	December 31, 2025				December 31, 2024
Term Loan Due 2032	$	2,094,750			$	—
Senior Notes Due 2032		600,000				—
Term Loan Due 2025		—				191,979
Term Loan Due 2028		—				2,292,856
Revolving credit facility		—				100,000
Gross debt (5)	$	2,694,750			$	2,584,835
Less: Cash and cash equivalents		282,029				110,552
Net debt (Non-GAAP) (6)	$	2,412,721			$	2,474,283
Adjusted EBITDA (Non-GAAP) for the year ended	$	688,415			$	627,442
Net leverage (Non-GAAP) (7)	3.5x				3.9x

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited; $ in thousands, except per share amounts)
Reconciliation of Net Income (Loss) to Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share
	Three Months Ended December 31,								Year Ended December 31,
	2025				2024				2025				2024
Net income (loss)	$	49,573			$	(20,742	)		$	127,933			$	(73,876	)
Adjusted to add (deduct):
Non-cash interest		6,625				183				23,533				1,735
GAAP provision for income taxes		5,662				5,423				11,276				18,863
Amortization		34,660				49,037				162,401				168,518
Stock-based compensation expense		8,202				7,209				31,823				27,552
Acquisition, site closure expenses, and idle facility expenses (1)		538				538				5,238				2,112
Restructuring and other charges		2,470				493				4,201				2,249
Loss on refinancing (2)		—				—				31,365				—
Charges (credit) related to legal matters, including interest, net (3)		—				1,783				(390	)			96,819
Asset impairment charges		134				176				23,022				1,372
Increase in tax receivable agreement liability		12,289				23,961				6,588				50,680
Other (4)		(10,568	)			964				(9,729	)			150
Provision for income taxes (8)		(26,792	)			(18,262	)			(92,514	)			(66,278	)
Net income attributable to non-controlling interests		(14,497	)			(10,339	)			(55,876	)			(43,010	)
Adjusted net income (Non-GAAP)	$	68,296			$	40,424			$	268,871			$	186,886
Weighted average diluted shares outstanding (Non-GAAP) (9)		328,094				324,099				324,805				320,645
Adjusted diluted earnings per share (Non-GAAP)	$	0.21			$	0.12			$	0.83			$	0.58

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited)
Explanations for Non-GAAP Reconciliations
(1)	Acquisition, site closure, and idle facility expenses for the three months and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three months and year ended December 31, 2024 primarily included rent for vacated properties.
(2)	For the year ended December 31, 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Note 5. below for additional information.
(3)	For the year ended December 31, 2024, charges related to legal matters, net were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States.
(4)	For the three months and year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain. System implementation expense of $0.3 million, formerly included in its own caption in the non-GAAP reconciliations, for the three months ended December 31, 2024 has been reclassified to the caption “other” to conform to the current period presentation. System implementation expense of $2.4 million and change in the fair value of contingent consideration of ($0.9 million), formerly included in their own captions in the non-GAAP reconciliations, for the year ended December 31, 2024 have been reclassified to the caption “other” to conform to the current period presentation.
(5)	On August 1, 2025, the Company borrowed $2.1 billion under new seven-year term loans (the “Term Loan Due 2032”) pursuant to an amendment to the Term Loan Credit Agreement and completed a private offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 at par (the “Senior Notes Due 2032”). The Company used the net proceeds of the Term Loan Due 2032 and the Senior Notes Due 2032 to refinance the Term Loan Due 2028 in full, to repay outstanding amounts borrowed under the revolving credit facility in full, and to pay related fees, premiums and expenses. Refer to Note 15. Debt in the Company’s 2024 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2024.
(6)	Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.
(7)	Net leverage was calculated by dividing net debt as of December 31, 2025 and December 31, 2024 by adjusted EBITDA for the years ended December 31, 2025 and 2024, respectively.
(8)	The non-GAAP effective tax rates for the three months and year ended December 31, 2025 were 28.2% and 25.6%, respectively. The non-GAAP effective tax rates for the three months and year ended December 31, 2024 were 31.1% and 26.2%, respectively.
(9)	Weighted average diluted shares outstanding for the three months and year ended December 31, 2025 and 2024 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities).

Amneal Pharmaceuticals, Inc. Affordable Medicines Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Three Months Ended December 31, 2025												Three Months Ended December 31, 2024
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	436,650			$	—			$	436,650			$	439,296			$	—			$	439,296
Cost of goods sold (2)		285,858				(11,288	)			274,570				261,196				(11,595	)			249,601
Gross profit		150,792				11,288				162,080				178,100				11,595				189,695
Gross margin %		34.5	%							37.1	%			40.5	%							43.2	%
Selling, general and administrative (3)		37,269				(2,472	)			34,797				33,915				(1,909	)			32,006
Research and development (4)		28,010				(671	)			27,339				48,598				(674	)			47,924
Intellectual property legal development expenses		1,320				—				1,320				1,907				—				1,907
Restructuring and other charges		2,198				(2,198	)			—				—				—				—
Charges related to legal matters, net		—				—				—				1,783				(1,783	)			—
Other operating income		(1	)			—				(1	)			—				—				—
Operating income	$	81,996			$	16,629			$	98,625			$	91,897			$	15,961			$	107,858

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the three months ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($0.9 million in each period), amortization expense ($10.4 million and $10.6 million), and asset impairment charges (none and $0.1 million).
(3)	Adjustments for the three months ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($1.8 million and $1.4 million), site closure costs ($0.5 million in each period), and asset impairment charges ($0.2 million and none).
(4)	Adjustments for the three months ended December 31, 2025 and 2024 were comprised of stock-based compensation expense.

Amneal Pharmaceuticals, Inc. Affordable Medicines Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Year Ended December 31, 2025												Year Ended December 31, 2024
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	1,745,524			$	—			$	1,745,524			$	1,685,263			$	—			$	1,685,263
Cost of goods sold (2)		1,061,600				(45,409	)			1,016,191				1,011,363				(46,718	)			964,645
Gross profit		683,924				45,409				729,333				673,900				46,718				720,618
Gross margin %		39.2	%							41.8	%			40.0	%							42.8	%
Selling, general and administrative (3)		142,383				(8,812	)			133,571				129,578				(7,160	)			122,418
Research and development (4)		156,013				(2,816	)			153,197				171,771				(2,587	)			169,184
Intellectual property legal development expenses		7,389				—				7,389				5,685				—				5,685
Restructuring and other charges		2,971				(2,971	)			—				70				(70	)			—
(Credit) charges related to legal matters, net (5)		(390	)			390				—				96,692				(96,692	)			—
Other operating income		(5,240	)			—				(5,240	)			—				—				—
Operating income	$	380,798			$	59,618			$	440,416			$	270,104			$	153,227			$	423,331

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($3.8 million and $3.6 million), amortization expense ($40.9 million and $41.8 million), and asset impairment charges ($0.7 million and $1.3 million).
(3)	Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($6.5 million and $5.1 million), site closure expenses ($2.1 million in each period), and asset impairment charges ($0.2 million and none).
(4)	Adjustments for the years ended December 31, 2025 and 2024 were comprised of stock-based compensation expense.
(5)	Adjustment for the year ended December 31, 2024 was primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States.

Amneal Pharmaceuticals, Inc. Specialty Segment Reconciliation of GAAP to Non-GAAP Operating Results (unaudited; $ in thousands)
	Three Months Ended December 31, 2025												Three Months Ended December 31, 2024
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	166,928			$	—			$	166,928			$	120,836			$	—			$	120,836
Cost of goods sold (1)		63,229				(22,586	)			40,643				59,537				(36,224	)			23,313
Gross profit		103,699				22,586				126,285				61,299				36,224				97,523
Gross margin %		62.1	%							75.7	%			50.7	%							80.7	%
Selling, general and administrative (2)		40,843				(491	)			40,352				30,129				(293	)			29,836
Research and development (2)		6,809				(81	)			6,728				5,667				(257	)			5,410
Intellectual property legal development expenses		91				—				91				(55	)			—				(55	)
Restructuring and other charges		—				—				—				493				(493	)			—
Operating income	$	55,956			$	23,158			$	79,114			$	25,065			$	37,267			$	62,332

(1)	Adjustments for the three months ended December 31, 2025 and 2024 were comprised of amortization expense.
(2)	Adjustments for the three months ended December 31, 2025 and 2024 were comprised of stock-based compensation expense.

Amneal Pharmaceuticals, Inc. Specialty Segment Reconciliation of GAAP to Non-GAAP Operating Results (unaudited; $ in thousands)
	Year Ended December 31, 2025												Year Ended December 31, 2024
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	528,508			$	—			$	528,508			$	445,749			$	—			$	445,749
Cost of goods sold (1)		245,915				(136,713	)			109,202				202,821				(117,573	)			85,248
Gross profit		282,593				136,713				419,306				242,928				117,573				360,501
Gross margin %		53.5	%							79.3	%			54.5	%							80.9	%
Selling, general and administrative (2)		135,715				(1,812	)			133,903				109,658				(1,048	)			108,610
Research and development (3)		30,162				(3,511	)			26,651				18,943				(1,058	)			17,885
Intellectual property legal development expenses		243				—				243				160				—				160
Restructuring and other charges		471				(471	)			—				1,517				(1,517	)			—
Other operating income		—				—				—				(930	)			930				—
Operating income	$	116,002			$	142,507			$	258,509			$	113,580			$	120,266			$	233,846

(1)	Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of amortization expense ($114.6 million and $117.6 million) and asset impairment charges ($22.1 million and none).
(2)	Adjustments for the years ended December 31, 2025 and 2024 were comprised of stock-based compensation expense.
(3)	Adjustments for the years ended December 31, 2025 and 2024, respectively, were comprised of stock-based compensation expense ($0.4 million and $1.1 million) and site closure costs ($3.1 million and none).

Amneal Pharmaceuticals, Inc. AvKARE Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Three Months Ended December 31, 2025												Three Months Ended December 31, 2024
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	210,741			$	—			$	210,741			$	170,386			$	—			$	170,386
Cost of goods sold		168,042				—				168,042				146,912				—				146,912
Gross profit		42,699				—				42,699				23,474				—				23,474
Gross margin %		20.3	%							20.3	%			13.8	%							13.8	%
Selling, general and administrative (2)		17,169				(2,700	)			14,469				16,015				(3,546	)			12,469
Operating income	$	25,530			$	2,700			$	28,230			$	7,459			$	3,546			$	11,005

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the three months ended December 31, 2025 and 2024 were comprised of amortization expense.

Amneal Pharmaceuticals, Inc. AvKARE Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Year Ended December 31, 2025												Year Ended December 31, 2024
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	744,728			$	—			$	744,728			$	662,945			$	—			$	662,945
Cost of goods sold		597,937				—				597,937				559,335				—				559,335
Gross profit		146,791				—				146,791				103,610				—				103,610
Gross margin %		19.7	%							19.7	%			15.6	%							15.6	%
Selling, general and administrative (2)		63,176				(10,799	)			52,377				60,709				(14,182	)			46,527
Operating income	$	83,615			$	10,799			$	94,414			$	42,901			$	14,182			$	57,083

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the years ended December 31, 2025 and 2024 were comprised of amortization expense.

FAQ

What were Amneal (AMRX) Q4 2025 results and EPS?

Amneal reported Q4 2025 net revenue of $814 million and GAAP diluted EPS of $0.11. According to the company, adjusted diluted EPS was $0.21, driven by higher revenue and lower interest expense.

What were Amneal (AMRX) full‑year 2025 financial highlights?

Full‑year 2025 net revenue was $3.02 billion and GAAP net income was $72 million. According to the company, adjusted diluted EPS totaled $0.83, with adjusted EBITDA of $688 million.

What guidance did Amneal (AMRX) give for 2026 revenue and EBITDA?

Amneal provided 2026 guidance of $3.05–3.15 billion in net revenue and $720–760 million in adjusted EBITDA. According to the company, guidance assumes AvKARE and product launch timing assumptions.

How did Amneal (AMRX) perform across business segments in 2025?

Specialty grew 19%, Affordable Medicines grew 4%, and AvKARE grew 12%. According to the company, Specialty strength was driven by CREXONT and UNITHROID.

Why do Amneal’s non‑GAAP and GAAP results differ for 2025?

Non‑GAAP measures exclude certain items, producing adjusted net income of $269 million versus GAAP net income of $72 million. According to the company, adjustments include acquisition, restructuring, and other items.

When and how can investors access Amneal’s Feb. 27, 2026 earnings call?

Amneal hosted a conference call and live webcast on Feb. 27, 2026 at 8:30 AM ET. According to the company, the webcast and replay are available on its investor relations website.